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Abstract In women, estrogen (E2) exerts a clinically relevant 
anti-atherogenic effect. The atheroprotective ffects of E2 are 
mediated both by E2-induced changes in systemic factors and by 
direct effects of E2 on the blood vessel wall. In studies to charac- 
terize E2 signaling pathways in vascular smooth muscle cells 
(NSMC), we recently demonstrated that human VSMC express 
a functional estrogen receptor [1]. In the present study, we applied 
a reverse transcription/PCR-based strategy to identify isoforms 
of the E2 receptor in human VSMC. We now report that in 
addition to the classical E2 receptor, human VSMC derived from 
both mammary artery and saphenous vein express an estrogen 
receptor isoform containing an in-frame deletion of Exon 4 
(ERA4). RNase protection assays confirm the presence of ERA4 
message in VSMC and demonstrate it is nearly as abundant as 
the classical E2 receptor. Transient transfection experiments in 
VSMC and HeLa cells demonstrate that, in contrast o the clas- 
sical 67 kDa nuclear-localized E2 receptor, ERA4: (a) is a 55 
kDa protein that is widely distributed throughout he cell; (b) does 
not transactivate an E2 response lement-driven reporter plasmid 
in response to E2; and (c) does not modulate transactivation of 
the ERE-reporter by the classical (wild type) estrogen receptor. 
Thus, human VSMC express an E2 receptor isoform that does 
not appear to alter gene transcription. The presence of a novel 
isoform of the E2 receptor may have important implications for 
studies of E2-mediated signaling in VSMC. 
K,T words: Estrogen; Steroid hormone receptor; 
Signal transduction; Vascular biology 
1. Introduction 
lschemic ardiovascular disease is the leading cause of death 
t'o~ adults in the United States. A number of observational 
epidemiological studies have demonstrated postmenopausal es- 
trogen replacement therapy in women can decrease the inci- 
dence of myocardial infarction and cardiac death by 35-50% 
[2-6]. These epidemiologic studies are supported further by 
animal studies demonstrating E2-mediated inhibition of exper- 
imentally induced atherosclerosis [7-12,46]. The atheroprotec- 
tix e effects of E2 are generally believed to be mediated in part 
b3 effects of E2 on systemic factors such as serum lipid levels 
[2.13,14]. However, systemic effects of estrogens do not account 
fo ~" the majority of the observed atheroprotective effects of E2 
[2.3,15,16]. In an effort to reveal additional pathways that may 
mediate the atheroprotective effects of E2, direct effects of E2 
ol ~, vascular cells are currently being investigated (reviewed in 
[1 ']). 
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Direct effects of E2 on vascular cell function were first sug- 
gested decades ago [7,18] and have since been shown both in 
whole animal and in vitro studies [10,19-30]. However, the 
signaling pathways involved in the direct effects of E2 on vascu- 
lar cells are not yet characterized. In non-vascular cells, most 
E2-mediated effects are thought o result from ligand-induced 
activation of the intracellular E2 receptor, a transcription fac- 
tor capable of regulating expression of genes whose regulatory 
elements contain a consensus E2 receptor binding sequence 
(reviewed in [31-34]). Human vascular smooth muscle cells are 
now known to express an E2 receptor [1,35]. 
Of interest, earlier studies uggest the presence of multiple E2 
binding activities in vascular tissue [18,36,37], but the identity 
of E2 binding proteins other than the classical E2 receptor 
remains unknown. Although only the wild type E2 receptor is 
known to bind E2 and transduce E2-mediated signals in normal 
human tissues, a number of E2 receptor variant mRNAs now 
have been identified in breast cancer cells (reviewed in [3840]). 
One such mRNA variant, containing an in-frame deletion of 
Exon 4 (ERA4) also recently has been identified in rat brain 
[41]. These findings suggest some tissues may express variant 
E2 receptors in addition to the classical E2 receptor. In the 
present study, we demonstrate the presence of ERA4 mRNA 
in human VSMC. This report represents the first demonstra- 
tion of an E2 receptor isoform in normal, non-reproductive 
human tissue. 
2. Experimental 
2.1. Cell culture 
VSMC were cultured, as described [1] from specimens of human 
saphenous vein and mammary artery obtained from both males and 
females at the time of cardiothoracic surgery. Cells were maintained in
phenol red-free DMEM containing 10% FBS with an E2 content less 
than 2.6 × 10 " M (Hyclone Laboratories, Inc., Logan, UT). Cells were 
identified as VSMC by their characteristic morphology and by im- 
munostaining with anti-smooth muscle specific actin (Sigma, St. Louis, 
MO), and were harvested for all experiments at passage 2 or less. 
MCF-7 cells (derived from a human breast carcinoma) known to con- 
tain a high level of E2 receptor, and HeLa cells (derived from human 
cervical carcinoma) that do not express the E2 receptor ([42], and see 
Results), were maintained in DMEM containing 10% FBS. 
2.2. Reverse transcription and PCR 
Total cellular RNA was harvested by a commercially available gua- 
nidinium thiocyanate-based method as described [1]. Reverse transcrip- 
tion was carried out by the random priming method using 16/2g of 
DNase-treated total RNA (Superscript reverse transcriptase, Gibco- 
BRL, Grand Island, NY). PCR was performed on an aliquot of the 
reverse transcription reaction using primers ER3 and ER4 (ER3; 5'- 
CATAACGACTATATGTGTCCAGCC nucleotides 646-670, and 
ER4; 5'-AACCGAGATGATGTAGCCAGCCGC nucleotides 1280- 
1304 of the E2 receptor; cf. Fig. 1) and the following protocol: hot start 
at 94°C × 2 min, 30 cycles of 94°C × 30 s, 65°C x 30 s, 72°C x 30 s, and 
a final extension of 72°C × 5 min. An aliquot of this PCR reaction was 
then reamplified using the same protocol as above with ER3 and the 
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Fig. 1. Summary of the reverse transcription/PCR based strategy to identify E2 receptor isoforms in VSMC. Shown are the intron/exon borders and 
important functional domains encoded by Exon 4. Using primers ER3 and ER5, PCR amplification ofVSMC cDNA encoding the wild-type receptor 
produces a 598 bp fragment, whereas amplification of cDNA encoding the receptor isoform lacking Exon 4 produces a 261 bp product. Note the 
position of the XbaI site ~ 100 bp distal to the Exon 4/Exon 5 splice junction, and the HindlII site contained within Exon 4. 
nested primer ER5 (ER5; 5'-CCTGGTTCCTGTCCAAGAGCAAGT 
nucleotides 1220-1244 of the E2 receptor; cf. Fig. 1). 
2.3. Southern blotting 
The products of the PCR reaction were separated by agarose gel 
electrophoresis and transferred to nitrocellulose membrane. The mem- 
brane was then hybridized at 46°C overnight with a radiolabeled 134 
bp probe (methods as described; [1]). The probe was made by restriction 
digestion of human E2 receptor cDNA (kind gift of Myles Brown) with 
BgllI and XbaI (base pairs 1135 1269 of the E2 receptor cDNA). After 
washing with 0.1% SSC and 0.1% SDS, the membrane was analyzed by 
Phosphorlmaging (Molecular Dynamics, Sunnyvale, CA). 
2.4. Subcloning and sequencing of PCR products 
PCR products were directly ligated into the pCR II cloning vector 
(Invitrogen, San Diego, CA). The resulting colonies were screened first 
by restriction digestion, and subsequently b Southern blotting for the 
presence of E2 receptor-related sequences. Positive clones were con- 
firmed by sequencing using the dideoxy chain termination method, 
according to the manufacturer's in tructions (Sequenase; United States 
Biochemical, Cleveland, OH). 
2.5. RNase protection assays 
A radiolabeled RNA probe, complementary to 261 bp of the ERA4 
sequence was produced by in vitro transcription (methods as described, 
[1] of the PCR product subcloned into the pCR II vector (Invitrogen, 
San Diego, CA). This probe was designed to flank symmetrically the 
Exon3/Exon5 splice site and thus allow discrimination between wild 
type ER and ERA4 (see Fig. 2). RNase protection assays were carried 
out as described [1]. The relative proportion of ERA4 and wild-type 
receptor message was determined by quantitative analysis of 
Phosphorlmages independently for both VSMC and MCF-7 cells. 
type E2 receptor cDNA driven by an SV40 promotor); (b) pSV40-ERA4 
(described above); or (c) pHEGO(-), (control plasmid derived from 
pHEGO by excision of the E2 receptor cDNA). Cells were harvested 
36 h after transfection and assayed either by Western blotting or by 
immunofluorescent staining, (methods as described [1]), using two dif- 
ferent anti-E2 receptor antibodies (D75 and D547 [43]; kind gift of 
Geoffrey Greene). To examine the potential transcriptional transactiva- 
tion potential of the E2 receptors, cells were electroporated with the 
reporter plasmid ERE-Luc (containing an E2 response lement (ERE) 
driving expression of the luciferase gene (originally VI9TK3 [44]; kind 
gift of C. Glass), and one or both of the expression plasmids pHEGO 
or pSV40-ERA4, as described [1]. Following transfection, cells were 
treated with hormone-containing media 36 h prior to harvest for deter- 
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2.6. Transient ranafections 
The expression plasmid pSV40-ERA4 was constructed by cloning a 
restriction fragment encoding the ERA4 cDNA into an appropriately 
digested expression plasmid for the wild type E2 receptor (pHEGO; 
kind gift of Myles Brown) and used to express full length ERA4. In 
brief, a portion of the ERA4 coding sequence extending from nucleotide 
8 to 1244 was amplified by PCR, digested with SmaI and XbaI and 
ligated into a similarly digested pHEGO vector. To identify subclones 
that represented the correct ERA4 plasmid, colonies were screened by 
restriction digestion and Southern blotting, and subsequently con- 
firmed by sequencing. 
VSMC or HeLa cells were transfected by electroporation, essentially 
as described [1]. For protein expression studies, cells were electropo- 
rated with one of the following expression plasmids: (a) pHEGO (wild- 
1 2 3 4 
VSMC cDNA pHEGO 
Fig. 2. Reverse transcription/PCR detects two distinct estrogen recep- 
tor-related messages in human VSMC. RT/PCR products were ampli- 
fied using primers that span exon 4 and resolved by agarose gel electro- 
phoresis. Amplification of cDNA derived from human VSMC pro- 
duced two dominant bands, one of ~ 600 bp and one of~ 260 bp (lane 1). 
Digestion of the PCR products with XbaI reduced the size of the bands 
by ~ 100 bp (lane 2). The position of the RT/PCR amplified 598 bp 
fragment from the classical E2 receptor (pHEGO) is shown in lanes 3 
and 4 as a positive control (without and with digestion by XbaI, respec- 
tively). 
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Fi~. 3. Sequence analysis confirms the detected estrogen receptor 
iso orm in VSMC contains an in-frame deletion of Exon 4. The PCR 
pr~ ducts shown in Fig. 2 were subcloned and sequenced. Shown is the 
po:tion of the 260 bp PCR product sequence that demonstrates the 
dir :ct transition from exon 3 to exon 5 coding sequence. 
migration of luciferase activity [1]. Equivalent levels of receptor protein 
exl~ression were documented byWestern blotting. Equivalent transfec- 
tioa efficiency between treatment groups was ensured by aliquoting 
celis from a single electroporation to all treatment groups equally. This 
wa,~ confirmed in a subset of transfection experiments in which the 
pla ~mid CMV-CAT (containing the chloramphenical acetyl transferase 
(CAT) gene driven by the CMV promoter; kind gift of RS Williams) 
wa~ co-transfected and the luciferase values were normalized for CAT 
act ~vity. Control cells were treated with vehicle alone (0.02% ETOH). 
The" results of luciferase assays were normalized by comparison with 
co~trol cells for each individual experiment. Results were compared by 
Stl~dent's t-test with a P - 0.05 considered significant. 
3. Results and discussion 
f'o attempt to identify E2 receptor isoforms in human 
Del ta  4 
Wi ld  
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Fig. 4. RNase protection assay detects ERA4 message in human VSMC. 
REase protection analysis was performed with a radiolabeled probe 
complementary to 261 bp of the ERA4 sequence symmetrically flanking 
the exon 3/exon 5 splice junction. ERA4 message protects the full length 
probe, whereas the wild-type E2 receptor message protects only smaller 
fragments (see details in text). Shown is a representative Phosphor- 
Image demonstrating the presence of ERA4 mRNA in human VSMC 
(100 ¢tg total RNA). MCF-7 breast cancer cells (20/lg total RNA) were 
included as a positive control. An equivalent amount of yeast RNA 
which does not contain E2 receptor message served as a negative con- 
trol (data not shown). 
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Fig. 5. Immunoblot analysis of the ERA4 protein. HeLa cells (which 
lack endogenous E2 receptor; lane 1) were transfected with expression 
plasmids encoding either the wild-type E2 receptor (lane 2), ERA4 (lane 
3) or both receptors (lane 4). Identical quantities of cell lysates were 
analyzed by immunoblotting with anti-E2 receptor antibody D75. Wild 
type ER has an estimated Mr of 67 kDa, while the ERA4 protein has 
an apparent molecular weight of 54 kDa, (predicted Mr from primary 
sequence =55 kDa). 
VSMC, we employed a PCR-based scheme to screen cDNA 
reverse transcribed from total cellular RNA using primer pairs 
that span intron/exon junctions. PCR using a primer pair span- 
ning Exon 4 and its 5' and 3' splice sites (ER3/ER5; see Fig. 1), 
produced two predominant bands, one ~ 600 bp and one ~260 
bp long (Fig. 2, Lane 1). The 600 bp product corresponds to 
the predicted size of the fragment from the wild-type gene, and 
the 260 bp product is the predicted size of a PCR product from 
which Exon 4 is deleted (cf. Fig. 1). Similar results were ob- 
tained when either oligo-dT- or E2 receptor-specific primers 
were used to prime the reverse transcription reaction during 
first strand cDNA synthesis (data not shown). 
The two predominant PCR products were also characterized 
by restriction digestion analysis. Digestion with XbaI decreased 
the size of both bands by 100 bp as expected (Fig. 2, Lane 2; 
cf. Fig. 1). In addition, digestion with HndIII ,  whose binding 
site is contained within Exon 4 of the wild-type receptor, re- 
duced the size of the 600 bp product but not that of the 260 bp 
product (data not shown). The presence of E2 receptor se- 
quences within the PCR products shown in Fig. 2 was also 
confirmed by Southern blotting with radiolabeled probes de- 
rived from wild-type E2 receptor sequences (data not shown). 
Based on these preliminary screening experiments, the 600 bp 
and 260 bp bands shown in Fig. 2 were tentatively identified 
as portions of the native E2 receptor and an E2 receptor variant 
containing an Exon 4 deletion. To confirm this hypothesis, the 
PCR reaction products were directly subcloned and sequenced. 
Sequence analysis of the plasmid containing the 600 bp insert 
confirmed it as wild-type receptor (data not shown). Sequence 
analysis of the plasmid containing the smaller fragment (pER- 
260) identified it as ERA4, an isoform of the wild-type receptor 
in which the coding sequence contained within Exon 4 is pre- 
cisely spliced out (Fig. 3). 
To quantify the abundance of ERA4 message in RNA de- 
rived from native VSMC, RNase protection analysis was un- 
dertaken using a radiolabeled probe complementary to 260 bp 
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Fig. 6. The ERA4 protein is not confined to the nucleus. Shown are HeLa cells transfected with an expression plasmid for either the wild-type (A,C) 
or ERA4 (B,D) receptor and viewed by phase contrast (A,B) or immunofluorescence microscopy (C,D). Receptor protein was identified by 
immunostaining with the Anti-E2 receptor antibody D75. Note that unlike the wild-type receptor, the ERA4 protein is not confined to the nuclear 
compartment and appears diffusely distributed throughout the cell (Magn. = 40x). 
of the ERA4 sequence. The probe was designed to flank sym- 
metrically the Exon3/Exon5 splice site in ERA4 such that hy- 
bridization with the ERA4 mRNA would produce a protected 
fragment larger than those produced by hybridization with the 
wild type receptor (260 bp vs. two 130 bp fragments, respec- 
tively). This strategy prevents any degraded probe from being 
incorrectly identified as representing a receptor isoform. RNA 
prepared from low-passage, freshly cultured VSMC derived 
from either saphenous vein or mammary artery was used in all 
RNase protection assays. The representative RNase protection 
assay shown in Fig. 4 demonstrates human VSMC make signif- 
icant levels of ERzl4 mRNA. No protected fragment of this size 
was detected when a comparable amount of yeast RNA was 
used as a negative control (data not shown). Quantitative anal- 
ysis of RNase protection assays performed on VSMC obtained 
from both males and females demonstrates a ratio of ERA4/ 
wild type E2 receptor of 0.64 + 0.11 (n = 10). The ratio of ERA4 
to wild type E2 receptor in MCF-7 cells, for comparison, is 
0.51 + 0.16 (n = 5). 
To explore the functional role of ERA4, the receptor isoform 
was next subcloned into a suitable xpression plasmid, pSV40- 
ERA4. The ability of pSV40-ERA4 to induce expression of full 
length ERA4 receptor protein was investigated in transient 
transfection studies using HeLa cells, which have no en- 
dogenous E2 receptor [42]. First, protein lysates of HeLa cells 
transfected with (a) control plasmid lacking receptor sequences; 
(b) pHEGO; (c) pSV40-ERA4; or (d) both receptor plasmids 
were analyzed by immunoblotting. As shown in Fig. 5, no 
receptor was detectable in HeLa cells transfected with the con- 
trol plasmid (lane 1). However, transfection of HeLa cells with 
pHEGO or pSV40-ERA4 resulted in approximately equivalent 
levels of expression of proteins with the predicted molecular 
weights of 67 kDa (native ER) or 55 kDa, (ERA4), respectively 
(Fig. 5, lanes 24).  Similar results were obtained when a differ- 
ent anti-E2 receptor antibody was used for immunoblotting 
(D574, [43] not shown). 
The intracellular distribution of ERA4 protein also was stud- 
ied by immunofluorescent staining of HeLa cells transfected 
with either the control plasmid pHEGO(-) ,  pHEGO, or 
pSV40-ERA4. As shown in Fig. 6, expression of the ERA4 
isoform resulted in a staining pattern strikingly different from 
that of the wild type receptor. The wild-type E2 receptor pro- 
tein was more widely distributed and confined to the nucleus 
(Panel C), whereas the ERA4 isoform was not predominantly 
nuclear (Panel D). HeLa cells transfected with the control vec- 
tor alone showed no specific staining (data not shown). 
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Fi ,. 7. ERA4 does not activate E2 response element-driven gene xpres- 
sit n or affect wild type E2 receptor t ansactivation in either VSMC or 
HtLa cells. Human VSMC and HeLa cells were co-transfected with an 
El,'~E-driven reporter plasmid along with expression plasmids encoding 
th~ wild-type receptor, ERd4, both receptors, or neither. Approxi- 
m,~tely equal receptor protein expression was documented byWestern 
bl, ,tting (cf. Fig. 5). Shown is the relative increase in luciferase activity 
in response to 48 h of l0 7 M E2 treatment. InVSMC, overexpression 
of the wild-type receptor markedly increases E2-induced ERE activa- 
tit n (as reported [1]), whereas overexpression of ERd4 has no effect on 
ERE activation by the endogenous receptor. In HeLa cells, the wild- 
tyl~e receptor, but not the ERA4 isoform, confers E2-induced activation 
of the ERE and again, the ERA4 does not effect ERE activation by 
wi d-type E2 receptor. 
3. '. ERA4 receptor &oform function 
To begin to define the function of ERA4, we first investigated 
th,~ potential transcriptional activity of the ERA4 isoform. Sev- 
erd functional domains of the wild-type E2 receptor are intact 
in the ERA4 isoform (e.g. DNA binding domain, transcrip- 
ti,,nal activation domains, dimerization motif) while others are 
oHitted (e.g. hinge region, nuclear localization signal and 56 of 
240 amino acids of the hormone binding domain; cf. Fig. 1). 
Therefore, ERA4 could be transcriptionally silent, or it could 
act as either a dominant negative or dominant positive E2 
re,ceptor. To investigate these possibilities, we used an ERE- 
L,,c based reporter system in cotransfection experiments with 
th,~ receptor isoforms. VSMC or HeLa cells were co-transfected 
w~th either (a) control plasmid; (b) pHEGO; (c) pSV40-ERA4; 
or (d) both receptor plasmids. Basal activity and E2-induced 
tr~,~nsactivation of the ERE were determined. Equivalent pro- 
te~n expression for both the wild type and A4 expression plas- 
m~ds was confirmed by western blotting (cf. Fig. 4 and data not 
shown). 
Consistent with our previous report [1], treatment of VSMC 
with 10 -7 M E2 resulted in a 2.6 _+ 0.42-fold increase in Lucif- 
erase activity, reflecting activation of the ERE by endogenous 
VSMC E2 receptor (Fig. 7). Overexpression of the EtLd4 
isoform did not alter the E2-induced activation of the ERE 
(2.7 + 0.35-fold increase; n = 8, P = n.s vs. control). In con- 
trast, and as shown previously [1], E2-induced activation of the 
ERE was markedly enhanced by overexpression f the wild 
type E2 receptor (16.7 + 2.7-fold activation; n = 5; P < 0.001 
vs. control or ERA4). In an additional series of transfections 
using VSMC, a CAT expression plasmid also was co-trans- 
fected, and all luciferase results were normalized to CAT activ- 
ity. In these experiments, the ratio of E2-induced activation of 
ERE in ERA4 transfected cells compared to sham transfected 
cells was 1.1 + 0.1 (P--0.75; n = 6), confirming the lack of 
effect of ERA4 on activation of the endogenous E2 receptor. 
To examine the transcriptional transactivation capacity of 
ERA4 in a cell that does not contain endogenous E2 receptors, 
HeLa cells were also studied. As shown in Fig. 7 (right panel), 
E2 does not activate the ERE in sham transfected cells. Overex- 
pression of the ERA4 isoform also does not confer E2-mediated 
activation to these cells. Transfection of HeLa cells with wild 
type ER (pHEGO) does, however, confer E2-mediated transac- 
tivation of the ERE. Again, the magnitude of this response is
unchanged when pHEGO and ERA4 are co-transfected 
(2.6 + 0.4 vs. 2.4 + 0.1, P = n.s, n = 3). Thus, in both VSMC 
and HeLa cells, ERA4 appears to be transcriptionally silent. 
We have demonstrated that human VSMC express mRNA 
for an isoform of the E2 receptor containing an in-frame dele- 
tion of Exon 4. Although anumber of E2 receptor variants have 
been identified in tumor cells, they have been considered to be 
mutations related to the transformed nature of the cells studied. 
The ERA4 variant was originally cloned from malignant tissue 
[39], and similarly considered to have resulted from a tumor- 
related mutation, until the recent report of ERA4 expression i  
normal uterine cells [40]. 
In previous tudies of ERA4, the presence of ERA4 message 
was detected by reverse transcription/PCR [39~1], but the level 
of ERA4 message xpression was not investigated. In the pres- 
ent study RNase protection assays were used to show the rela- 
tive proportion of wild type to ERA4 message is ~3:2. The 
presence and high relative proportion of ERA4 message in 
VSMC has a number of implications. First, it suggests previous 
studies of E2 receptor expression should be reassessed, since 
most methods capable of detecting the wild-type receptor (both 
antibody-based and oligonucleotide probe-based) also will 
likely detect ERA4. This has specific implications for immu- 
nohistochemical studies of the intracellular receptor distribu- 
tion since unlike the wild-type receptor, ERA4 is diffusely dis- 
tributed. The heterogenous cytoplasmic staining noted previ- 
ously in VSMC [1,35] thus may in part represent ERA4 protein 
within the cells. Definitive investigation of this possibility will 
require development of ERA4-specific antibodies. 
Despite the present demonstration f ERA4 expression in 
VSMC and previous reports identifying ERA4 in other cell 
types, a number of important questions regarding ERA4 re- 
main. For example, due to a lack of ERA4-specific antibodies, 
ERA4 protein expression has not yet been characterized in any 
cell type. A second issue that has not yet been adequately 
explored is what is the function of the ERA4 isoform. Although 
it is possible ERA4 serves no function, the relatively high abun- 
dance of ERA4 message compared to wild-type message makes 
this less likely. Several functional possibilities are made unlikely 
or excluded by the present data. Though it was speculated 
initially that ERA4 might be a constitutively active orphan 
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receptor with a basal level of transcription of E2-responsive 
genes [41], in the current study overexpression f ERA4 did not 
increase the basal activity of ERE reporters in either HeLa cells 
or VSMC. Also, ERA4 by itself was not capable of transcrip- 
tional transactivation f the ERE in response to E2, nor did it 
affect the ability of the wild-type receptor to do so. These 
findings are consistent with those of Koehorst et al who studied 
the ERA4 variant from MCF-7 cells [40]. These authors demon- 
strate further, that overexpressed ERA4 protein binds neither 
the ERE nor E2. Our data do not exclude the possibility that 
ERA4 is an orphan receptor, that (a) recognizes a DNA se- 
quence different han the ERE (though the DNA binding do- 
main of the protein is essentially intact); or (b) binds to a ligand 
other than 17fl-estradiol. It is also possible ERA4 might alter 
transcriptional events in a hormone-independent fashion fol- 
lowing activation by an alternative pathway, as has been seen 
for a hormone-independent E2 receptor activation by dopa- 
mine [45]. 
In summary, the data presented here show that human vas- 
cular smooth muscle cells express abundant ERA4 message and 
support he hypothesis that this receptor variant is an E2 recep- 
tor isoform. The protein, when expressed, is not confirned to 
the nucleus, nor does it lead to E2-responsive transcriptional 
transactivation or influence transactivation by wild type E2 
receptor. Further studies will address any relationship between 
the ERA4 protein and the low-affinity E2 binding sites previ- 
ously reported in vascular cells, as well as the rapid, non- 
genomic effects of E2 on vascular smooth muscle cell tone [17]. 
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